ArticleAdvances in therapy2026
Real-World Assessment of Healthcare Resource Utilization-Defined Manic and Depressive Events Among Patients with Bipolar I Disorder Treated with Cariprazine Versus Aripiprazole.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAtypical antipsychotics (AAs) are first-line treatments for bipolar I disorder (BP-I). While cariprazine is approved in the US for the treatment of both BP-I manic/mixed and depressive episodes, most other AAs are only approved for one affective pole but are utilized across the disease spectrum. For example, aripiprazole is only approved for BP-I manic/mixed episodes. This real-world analysis compared the rates of healthcare resource utilization (HRU)-defined manic and depressive events among patients treated with cariprazine versus aripiprazole.
methodsA retrospective observational cohort study was conducted using IQVIA
resultsThe cariprazine cohort included 2530 patients with 604 manic and 884 depressive overall events, while the aripiprazole cohort included 7057 patients with 2301 manic and 2958 depressive overall events. The overall rate of HRU-defined manic events PPY was 37% lower in the cariprazine versus aripiprazole cohort [RR (95% CI): 0.63 (0.43, 0.94); P < .05]. Rates of outpatient-defined manic events were also significantly lower for cariprazine versus aripiprazole [0.62 (0.39, 0.94); P < .05], whereas inpatient and ED-defined manic events were similar. The overall rate of HRU-defined depressive events PPY was 28% lower for cariprazine than aripiprazole [0.72 (0.59, 0.90); P < .001], which was driven by the significantly lower rate of outpatient-defined events for cariprazine [0.72 (0.58, 0.89); P < .001]; inpatient- and ED-defined events were similar.
conclusionIn this real-world analysis, overall rates of HRU-defined manic and depressive events were significantly lower for cariprazine versus aripiprazole, demonstrating the relative real-world value of cariprazine versus aripiprazole, and underscoring the potential HRU benefits of cariprazine's full-spectrum efficacy.
Indexed as
Identifiers
42606795What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.